Key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency (PDCD) were presented. DCA was well-tolerated, even upon chronic administration for ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback